Related Experiment Video
Updated: Aug 19, 2025

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells
Published on: April 25, 2018
Long Non-coding RNA H19 Recruits NFYB to Activate MBTD1 and Regulate Doxorubicin Resistance in Lymphoma Cells
Lili Feng1, Qinying Yan2, Xiaofang Xu3
1Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People's Republic of China.
Abstract:
Doxorubicin (DOX) is a first-line chemo drug for lymphoma treatment. DOX resistance remains a major obstacle leading to treatment failure. This study explores the interactions of the long non-coding RNA H19 (H19)/nuclear transcription factor Y subunit beta (NFYB)/mbt domain containing 1 (MBTD1) axis in DOX resistance in lymphoma cells. Bioinformatics prediction indicated a correlation between MBTD1 and advanced lymphoma stage. Elevated MBTD1 expression was detected in lymphoma cells compared to normal lymphocytes, especially in DOX-resistant lymphoma cells (OCI-Ly8/DOX and SU-DHL-2/DOX). MBTD1 silencing weakened DOX resistance in the drug-resistant cells. Bioinformatics analysis further indicated a candidate H19/NFYB/MBTD1 axis in lymphoma. Luciferase and ChIP-qPCR assays validated that NFYB bound to MBTD1 promoter to activate the MBTD1 transcription. H19 recruited NFYB to increase MBTD1 expression without altering NFYB levels. H19 silencing suppressed growth of the DOX-resistant cells in vitro and in vivo. Either NFYB or MBTD1 activation restored the DOX resistance and malignant growth of the cells. In summary, this paper demonstrates that H19 activates MBTD1 transcription in a NFYB-dependent manner to promote DOX resistance in lymphoma cells.
Insights
This study reveals how the H19 long non-coding RNA promotes doxorubicin (DOX) resistance in lymphoma by activating MBTD1 expression via NFYB. Targeting this H19/NFYB/MBTD1 axis may overcome drug resistance in lymphoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Doxorubicin (DOX) is a key chemotherapy for lymphoma.
- Drug resistance to DOX significantly hinders treatment efficacy.
- Understanding resistance mechanisms is crucial for improving lymphoma therapy.
Purpose of the Study:
- To investigate the role of the H19/NFYB/MBTD1 axis in DOX resistance in lymphoma cells.
- To elucidate the molecular mechanisms underlying this interaction.
- To identify potential therapeutic targets for overcoming DOX resistance.
Main Methods:
- Bioinformatics analysis for gene correlation and pathway prediction.
- Cell culture of DOX-resistant lymphoma cell lines (OCI-Ly8/DOX, SU-DHL-2/DOX).
- Gene silencing (siRNA), luciferase reporter assays, ChIP-qPCR, in vitro and in vivo experiments.
Main Results:
- MBTD1 expression is elevated in lymphoma, correlating with advanced stage and DOX resistance.
- MBTD1 silencing reduced DOX resistance in lymphoma cells.
- H19 recruits NFYB to activate MBTD1 transcription, promoting DOX resistance and cell growth.
- Silencing H19 inhibited DOX-resistant cell growth in vitro and in vivo.
Conclusions:
- The H19/NFYB/MBTD1 axis plays a critical role in promoting DOX resistance in lymphoma.
- H19 upregulates MBTD1 via NFYB-dependent transcriptional activation.
- This axis represents a potential therapeutic target for overcoming DOX resistance in lymphoma.
More Related Videos
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
lncRNA - Long Non-coding RNAs
Abnormal Proliferation
Master Transcription Regulators
Formation of Muscle Fibers from Myoblasts
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
The Nucleolus
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...